ReviewFrontiers in microbiology2025
Faecalcrobiota metabolites: emerging insights into cancer radiotherapy outcomes.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The connection between gut microbiota and the onset, progression, and management of cancer is receiving increasing attention. Gut microbiota metabolites serve as crucial mediators that influence the cancer process by modulating immune responses and metabolic pathways. Research has shown that these metabolites significantly affect cancer development, prognosis and therapy. For example, the effectiveness and side effects of radiotherapy are closely linked to the metabolites produced by gut microbiota. Radiotherapy can disrupt the balance of gut microbiota, increase intestinal permeability, and trigger inflammatory responses, all of which may lead to adverse reactions such as damage to the intestinal mucosa and a compromised anti-cancer effect. This review emphasizes the role of gut microbiota metabolites in tumor formation and progression by affecting signaling pathways and the tumor immune microenvironment. It explores how these metabolites can influence the efficacy and side effects of radiotherapy and discusses innovative cancer treatment strategies that leverage gut microbiota metabolites. By integrating recent preclinical and clinical findings, the review proposes that incorporating colony modulation therapies into cancer treatment could enhance therapeutic strategies and provide patients with safer and more effective options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.